Sequence: KLALKLALKALKAALKLA
| Experiment Id | EXP000882 |
|---|---|
| Paper | Structural Requirements for Cellular Uptake and Antisense Activity of Peptide Nucleic Acids Conjugat |
| Peptide | KLA (MAP) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | 1 µM (conjugate in OptiMEM, 4 h incubation unless noted) |
| Rna Concentration | 1 µM (conjugate; covalent so same as peptide) |
| Mixing Ratio | covalent (1:1) |
| Formulation Format | covalent PNA–peptide conjugate |
| Formulation Components | Disulfide-linked conjugate: PNA-SS-KLA (peptide attached to N-terminus of PNA) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa pLuc 705 (luciferase/IVS2-705 splice-correction reporter) |
| Animal Model | |
| Administration Route | |
| Output Type | Luciferase splice-correction reporter |
| Output Value | ~5-fold vs naked PNA at 1 µM |
| Output Units | |
| Output Notes | At 1 µM, PNA-SS-KLA increased luciferase ~5-fold vs naked PNA (4 h incubation). Chloroquine post-treatment (100 µM, 24 h total) increased effect ~47-fold vs naked PNA. |
| Toxicity Notes | MAP-derived (KLA/RLA/ELA) conjugates showed cytotoxicity at higher concentrations (reported ~20% viability at 4 µM by MTT). |
| Curation Notes |